| Drug treatment for tuberculosis during pregnancy: safety considerations. | |
| | |
MedLine Citation:
|
PMID: 11444726 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Untreated tuberculosis in pregnancy poses a significant threat to the mother, fetus and family. Adherence to treatment is especially difficult in pregnancy because of the general fear of any medication and pregnancy-related nausea. Supervised treatment is especially helpful in encouraging adherence. All 4 first line drugs [isoniazid, rifampicin (rifampin), ethambutol and pyrazinamide] have an excellent safety record in pregnancy and are not associated with human fetal malformations. Drug-induced hepatitis, especially with isoniazid, is a significant problem in treating tuberculosis, not peculiar to pregnancy; close monitoring of liver function is recommended. Liver enzyme induction by rifampicin alters the metabolism of other drugs, e.g. methadone doses will need to be increased. Streptomycin should not be used in pregnancy, as perhaps 1 in 6 babies will have problems with hearing and/or balance. Ciprofloxacin has the best safety profile of second line drugs in the treatment of drug-resistant tuberculosis. Preventive treatment with isoniazid can be undertaken safely during pregnancy. Pyridoxine (vitamin B6) should be added to the drug treatment of tuberculosis in all pregnant women taking isoniazid. Neither tuberculin nor the bacille Calmette Guérin (BCG) vaccine are treatments for tuberculosis, but they play an important role in the management of the disease. Tuberculin testing is safe, but BCG vaccination should be avoided in pregnancy and instead given earlier in life. |
| | |
Authors:
|
G Bothamley |
Related Documents
:
|
19087116 - Neurologic birth defects after prenatal exposure to antiepileptic drugs. 9455716 - The pegasus project--a prospective cohort study for the investigation of drug use in pr... 12948456 - The australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. 10874386 - Impact of the consensus conference on polycythemia vera. an opportunity to change or a ... 10527826 - Localization and significance of urokinase plasminogen activator and its receptor in pl... 18238966 - Twin chorionicity and the risk of stillbirth. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Drug safety : an international journal of medical toxicology and drug experience Volume: 24 ISSN: 0114-5916 ISO Abbreviation: Drug Saf Publication Date: 2001 |
Date Detail:
|
Created Date: 2001-07-10 Completed Date: 2001-12-04 Revised Date: 2005-11-16 |
Medline Journal Info:
|
Nlm Unique ID: 9002928 Medline TA: Drug Saf Country: New Zealand |
Other Details:
|
Languages: eng Pagination: 553-65 Citation Subset: IM |
Affiliation:
|
East London Tuberculosis Service, Homerton Hospital, England. graham.bothamley@homerton-hospital.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antitubercular Agents / pharmacology, therapeutic use* BCG Vaccine / administration & dosage* Female Humans Patient Compliance Pregnancy Pregnancy Complications, Infectious / diagnosis, drug therapy*, prevention & control Recurrence Tuberculin Test Tuberculosis / diagnosis, drug therapy*, prevention & control |
| Chemical | |
Reg. No./Substance:
|
0/Antitubercular Agents; 0/BCG Vaccine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Comparative tolerability of pharmacological treatments for patent ductus arteriosus.
Next Document: Analysis of three-dimensional Doppler ultrasonographic quantitative measures for the discrimination ...